Sarepta Therapeutics’ (SRPT) Sell Rating Reiterated at HC Wainwright

HC Wainwright restated their sell rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Tuesday,Benzinga reports.

Other equities analysts have also issued research reports about the stock. Wedbush upped their target price on shares of Sarepta Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Guggenheim dropped their price objective on shares of Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Weiss Ratings restated a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. Mizuho upgraded Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $19.00 to $26.00 in a research report on Wednesday, November 5th. Finally, Robert W. Baird cut their price target on Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. Nine equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the company. According to MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Hold” and an average target price of $33.84.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $21.24 on Tuesday. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. Sarepta Therapeutics has a twelve month low of $10.41 and a twelve month high of $120.05. The business has a 50-day moving average price of $21.51 and a 200-day moving average price of $19.88. The firm has a market cap of $2.23 billion, a price-to-earnings ratio of -7.06, a price-to-earnings-growth ratio of 0.53 and a beta of 0.48.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.15). Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. The business had revenue of $399.36 million for the quarter, compared to the consensus estimate of $331.51 million. During the same period last year, the business posted $0.62 EPS. The firm’s revenue for the quarter was down 14.5% compared to the same quarter last year. As a group, equities research analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Insiders Place Their Bets

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the sale, the chief operating officer directly owned 193,300 shares in the company, valued at $4,312,523. This represents a 6.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. 7.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Large investors have recently modified their holdings of the stock. iSAM Funds UK Ltd bought a new stake in Sarepta Therapeutics in the third quarter worth $25,000. Ancora Advisors LLC raised its stake in shares of Sarepta Therapeutics by 200.0% in the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 1,000 shares during the period. Byrne Asset Management LLC bought a new stake in shares of Sarepta Therapeutics in the 3rd quarter worth about $33,000. Allworth Financial LP boosted its stake in shares of Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,721 shares during the period. Finally, Parallel Advisors LLC grew its holdings in Sarepta Therapeutics by 165.3% during the 3rd quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,256 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.